Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Population Pharmacokinetics of L-AmB in ECMO Patients
NCT06754436Phase 4Not yet recruiting
- Sponsor
- Beijing An Zhen Hospital
- Start
- Jan 2025
- Primary completion
- Nov 2025
- Modality
- Lipid-based Nanoparticles, Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of liposomal amphotericin b in invasive fungal infection (IFI), sponsored by Beijing An Zhen Hospital. Primary endpoint: Blood drug concentration of liposomal amphotericin B at 24 hours. Planned start Jan 2025; status: not yet recruiting.
02
Drugs
liposomal amphotericin b
03
Conditions
invasive fungal infection (IFI)
Beyond the preview
Go deeper on NCT06754436.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06754436.